Literature DB >> 9525989

Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model.

C C Silliman1, N F Voelkel, J D Allard, D J Elzi, R M Tuder, J L Johnson, D R Ambruso.   

Abstract

Transfusion-related acute lung injury (TRALI) is a serious complication of hemotherapy. During blood storage, lipids are generated and released into the plasma. In this study, the role of these lipids in TRALI was investigated using an isolated, perfused rat lung model. Rats were pretreated with endotoxin (LPS) or saline in vivo and the lungs were isolated, ventilated, and perfused with saline, or (a) 5% (vol/ vol) fresh human plasma, (b) plasma from stored blood from the day of isolation (D.0) or from the day of outdate (D.42), (c) lipid extracts from D.42 plasma, or (d) purified lysophosphatidylcholines. Lungs from saline or LPS-pretreated rats perfused with fresh (D.0) plasma showed no pulmonary damage as compared with saline perfused controls. LPS pretreatment/D.42 plasma perfusion caused acute lung injury (ALI) manifested by dramatic changes in both pulmonary artery pressure and edema. Incubation of LPS pre-tx rats with mibefradil, a Ca2+ channel blocker, or WEB 2170, a platelet-activating factor (PAF) receptor antagonist, inhibited ALI caused by D.42 plasma. Lung histology showed neutrophil sequestration without ALI with LPS pretreatment/saline or D.0 plasma perfusion, but ALI with LPS pretreatment/D.42 plasma perfusion, and inhibition of D.42 plasma induced ALI with WEB 2170 or mibefradil. A significant increase in leukotriene E4 was present in LPS-pretreated/D.42 plasma-perfused lungs that was inhibited by WEB 2170. Lastly, significant pulmonary edema was produced when lipid extracts of D.42 plasma or lysophosphatidylcholines were perfused into LPS-pretreated lungs. Lipids caused ALI without vasoconstriction, except at the highest dose employed. In conclusion, both plasma and lipids from stored blood produced pulmonary damage in a model of acute lung injury. TRALI, like the adult respiratory distress syndrome, may be the result of two insults: one derived from stored blood and the other from the clinical condition of the patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525989      PMCID: PMC508724          DOI: 10.1172/JCI1841

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.

Authors:  H O Heuer; J Casals-Stenzel; G Muacevic; K H Weber
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

2.  The NADPH oxidase of human polymorphonuclear leukocytes. Evidence for regulation by multiple signals.

Authors:  L C McPhail; C C Clayton; R Snyderman
Journal:  J Biol Chem       Date:  1984-05-10       Impact factor: 5.157

Review 3.  Adult respiratory-distress syndrome: changing concepts of lung injury and repair.

Authors:  J E Rinaldo; R M Rogers
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

4.  Measurement of peptidoleukotrienes in biological fluids.

Authors:  J Y Westcott; K Johnston; R A Batt; S E Wenzel; N F Voelkel
Journal:  J Appl Physiol (1985)       Date:  1990-06

5.  Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction.

Authors:  M Véniant; J P Clozel; P Hess; R Wolfgang
Journal:  J Cardiovasc Pharmacol       Date:  1991-02       Impact factor: 3.105

6.  Cytokine generation in stored platelet concentrates.

Authors:  G Stack; E L Snyder
Journal:  Transfusion       Date:  1994-01       Impact factor: 3.157

7.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.

Authors:  A W Ford-Hutchinson; M A Bray; M V Doig; M E Shipley; M J Smith
Journal:  Nature       Date:  1980-07-17       Impact factor: 49.962

8.  Metabolic, membrane, and functional responses of human polymorphonuclear leukocytes to platelet-activating factor.

Authors:  L M Ingraham; T D Coates; J M Allen; C P Higgins; R L Baehner; L A Boxer
Journal:  Blood       Date:  1982-06       Impact factor: 22.113

9.  Functional and metabolic activity of granulocytes from patients with adult respiratory distress syndrome. Evidence for activated neutrophils in the pulmonary circulation.

Authors:  G A Zimmerman; A D Renzetti; H R Hill
Journal:  Am Rev Respir Dis       Date:  1983-03

10.  Leukotrienes are potent constrictors of human bronchi.

Authors:  S E Dahlén; P Hedqvist; S Hammarström; B Samuelsson
Journal:  Nature       Date:  1980-12-04       Impact factor: 49.962

View more
  95 in total

1.  Fresh red blood cell transfusion and short-term pulmonary, immunologic, and coagulation status: a randomized clinical trial.

Authors:  Daryl J Kor; Rahul Kashyap; Richard B Weiskopf; Gregory A Wilson; Camille M van Buskirk; Jeffrey L Winters; Michael Malinchoc; Rolf D Hubmayr; Ognjen Gajic
Journal:  Am J Respir Crit Care Med       Date:  2012-01-26       Impact factor: 21.405

2.  Properties of stored red blood cells: understanding immune and vascular reactivity.

Authors:  Philip C Spinella; Rosemary L Sparrow; John R Hess; Philip J Norris
Journal:  Transfusion       Date:  2011-04       Impact factor: 3.157

3.  The association of early transfusion with acute lung injury in patients with severe injury.

Authors:  Daniel N Holena; Giora Netzer; Russell Localio; Robert J Gallop; Scarlett L Bellamy; Nuala J Meyer; Michael G S Shashaty; Paul N Lanken; Sandra Kaplan; Patrick M Reilly; Jason D Christie
Journal:  J Trauma Acute Care Surg       Date:  2012-10       Impact factor: 3.313

4.  Difference in autologous blood transfusion-induced inflammatory responses between acute normovolemic hemodilution and preoperative donation.

Authors:  Yoshifumi Kotake; Michiko Yamamoto; Midori Matsumoto; Takashige Yamada; Hiromasa Nagata; Hiroshi Morisaki; Junzo Takeda
Journal:  J Anesth       Date:  2009-02-22       Impact factor: 2.078

5.  Antibodies to major histocompatibility complex class II antigens directly prime neutrophils and cause acute lung injury in a two-event in vivo rat model.

Authors:  Marguerite R Kelher; Anirban Banerjee; Fabia Gamboni; Cameron Anderson; Christopher C Silliman
Journal:  Transfusion       Date:  2016-09-25       Impact factor: 3.157

6.  Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression.

Authors:  Karen K Lo; Erik A Bey; Biswantha Patra; Douglas D Benson; David A Boothman; Christopher C Silliman; Carlton C Barnett
Journal:  Ann Surg Oncol       Date:  2013-01-18       Impact factor: 5.344

7.  A case of transfusion-related acute lung injury induced by anti-human leukocyte antigen antibodies in acute leukemia.

Authors:  Sun Mi Jin; Moon Ju Jang; Ji Young Huh; Myoung Hee Park; Eun Young Song; Doyeun Oh
Journal:  Korean J Hematol       Date:  2012-12-24

8.  Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.

Authors:  Jumei Shi; Guido Tricot; Susann Szmania; Nancy Rosen; Tarun K Garg; Priyangi A Malaviarachchi; Amberly Moreno; Bo Dupont; Katharine C Hsu; Lee Ann Baxter-Lowe; Michele Cottler-Fox; John D Shaughnessy; Bart Barlogie; Frits van Rhee
Journal:  Br J Haematol       Date:  2008-10-16       Impact factor: 6.998

9.  Amantadine inhibits platelet-activating factor induced clathrin-mediated endocytosis in human neutrophils.

Authors:  Phillip C Eckels; Anirban Banerjee; Ernest E Moore; Nathan J D McLaughlin; Lynn M Gries; Marguerite R Kelher; Kelly M England; Fabia Gamboni-Robertson; Samina Y Khan; Christopher C Silliman
Journal:  Am J Physiol Cell Physiol       Date:  2009-03-18       Impact factor: 4.249

10.  Mirasol Pathogen Reduction Technology treatment does not affect acute lung injury in a two-event in vivo model caused by stored blood components.

Authors:  C C Silliman; S Y Khan; J Bradley Ball; M R Kelher; S Marschner
Journal:  Vox Sang       Date:  2009-11-25       Impact factor: 2.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.